Home » Archive by Category

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

Artificial embryonic stem cells have quality problems: study

July 2, 2014 – 10:00 am | Edit Post

Induced pluripotent stem cells have quality concerns, which may hinder use for therapy.

Meet our team: Rhiannon Bruni

July 2, 2014 – 7:33 am | Edit Post

This is an interview with Rhiannon Bruni, senior communications specialist at our La Jolla, Calif., campus.

Seragon purchased for up to $1.7 billion

July 2, 2014 – 6:35 am | Edit Post

San Diego developer of breast cancer drugs, was spun out of Aragon Pharma last year.

VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

July 2, 2014 – 5:21 am | Edit Post
VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

The big year for San Francisco, CA-based life sciences venture firm venBio just got bigger. Genentech, the big cancer drugmaker from the Bay Area, has agreed to buy a less than one-year-old San…

[[Click headline to continue reading.]]

Synchroneuron Nets $20M to Combat Drug-Induced Movement Disorder

July 2, 2014 – 4:55 am | Edit Post
Synchroneuron Nets $20M to Combat Drug-Induced Movement Disorder

With a few tweaks, Synchroneuron believes it’s been able to turn an old, flawed drug for alcoholism into a new one for a completely different disorder. Now the Waltham, MA-based startup has just…

[[Click headline to continue reading.]]

Some stem cell methods closer to “gold standard” than others

July 1, 2014 – 5:00 pm | Edit Post

LA JOLLA—Researchers around the world have turned to stem cells, which have the potential to develop into any cell type in the body, for potential regenerative and disease therapeutics.

Some stem cell methods closer to “gold standard” than others

July 1, 2014 – 5:00 pm | Edit Post

LA JOLLA—Researchers around the world have turned to stem cells, which have the potential to develop into any cell type in the body, for potential regenerative and disease therapeutics.

A possible partner for Scripps Research?

July 1, 2014 – 3:38 pm | Edit Post

Sanford-Burnham suggests it is willing to partner with the Scripps Research Institute.

A possible partner for Scripps Research?

July 1, 2014 – 3:38 pm | Edit Post

Sanford-Burnham suggests it is willing to partner with the Scripps Research Institute.

San Diego’s Ambrx Withdraws IPO, Citing Market Conditions

June 30, 2014 – 5:23 pm | Edit Post
San Diego’s Ambrx Withdraws IPO, Citing Market Conditions

Ambrx, a San Diego biotech developing antibody-drug conjugates to treat solid tumors and other diseases, said today it is withdrawing its planned IPO because of current market conditions. The company…

[[Click headline to continue reading.]]